Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases

European Journal of Preventive Cardiology

Volumn 19, Issue 4, 2012, Pages 864-873

  Westerink, Jan ^a   Van Der Graaf, Yolanda ^a   Faber, Daniël R ^a   Spiering, Wilko ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adiposity; thyroid stimulating hormone; vascular diseases

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; THYROTROPIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW UP; GROUPS BY AGE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTRAABDOMINAL FAT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; THYROID DISEASE; VASCULAR DISEASE; AGED; ANALYSIS OF VARIANCE; BLOOD; MIDDLE AGED; MORTALITY; NETHERLANDS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME;

ADIPOSITY; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; NETHERLANDS; OBESITY; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THYROTROPIN; TIME FACTORS; VASCULAR DISEASES;

EID: 84871686135     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711416045     Document Type: Article

References (42)

1. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004 ; 59 (1). 31-50
2. Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid. 2002 ; 12 (5). 421-425
3. Crowley WF, Ridgway EC, Bough EW, Francis GS, Daniels GH, Kourides IA, et al. Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med. 1977 ; 296 (1). 1-6
4. Gumieniak O, Perlstein TS, Hopkins PN, Brown NJ, Murphey LJ, Jeunemaitre X, et al. Thyroid function and blood pressure homeostasis in euthyroid subjects. J Clin Endocrinol Metab. 2004 ; 89 (7). 3455-3461
5. Jublanc C, Bruckert E, Giral P, Chapman MJ, Leenhardt L, Carreau V, et al. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis. 2004 ; 172 (1). 7-11
6. O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc. 1993 ; 68 (9). 860-866
7. Papaioannou GI, Lagasse M, Mather JF, Thompson PD. Treating hypothyroidism improves endothelial function. Metabolism. 2004 ; 53 (3). 278-279
8. Chiche F, Jublanc C, Coudert M, Carreau V, Kahn JF, Bruckert E. Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patients. Atherosclerosis. 2009 ; 203 (1). 269-276
9. Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Virdis A, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: A double-blind, placebo- controlled study. J Clin Endocrinol Metab. 2004 ; 89 (5). 2099-2106
10. Gussekloo J, van EE, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004 ; 292 (21). 2591-2599
11. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008 ; 148 (11). 832-845
12. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010 ; 304 (12). 1365-1374
13. Cikim AS, Oflaz H, Ozbey N, Cikim K, Umman S, Meric M, et al. Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid. 2004 ; 14 (8). 605-609
14. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf). 2004 ; 61 (2). 232-238
15. Asvold BO, Bjoro T, Nilsen TI, Gunnell D, Vatten LJ. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med. 2008 ; 168 (8). 855-860
16. Fox CS, Pencina MJ, D'Agostino RB, Murabito JM, Seely EW, Pearce EN, et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med. 2008 ; 168 (6). 587-592
17. Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab. 2005 ; 90 (7). 4019-4024
18. Kim MS, Small CJ, Stanley SA, Morgan DG, Seal LJ, Kong WM, et al. The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J Clin Invest. 2000 ; 105 (7). 1005-1011
19. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983 ; 67 (5). 968-977
20. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der GY. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999 ; 15 (9). 773-781
21. Stolk RP, Wink O, Zelissen PM, Meijer R, van Gils AP, Grobbee DE. Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord. 2001 ; 25 (9). 1346-1351
22. Asvold BO, Bjoro T, Nilsen TI, Vatten LJ. Tobacco smoking and thyroid function: A population-based study. Arch Intern Med. 2007 ; 167 (13). 1428-1432
23. Lippi G, Montagnana M, Targher G, Salvagno GL, Guidi GC. Relationship between thyroid status and renal function in a general population of unselected outpatients. Clin Biochem. 2008 ; 41 (7a8). 625-627
24. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000 ; 148 (2). 209-214
25. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 ; 286 (3). 327-334
26. Davies PH, Black EG, Sheppard MC, Franklyn JA. Relation between serum interleukina6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness. Clin Endocrinol (Oxf). 1996 ; 44 (2). 199-205
27. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999 ; 84 (1). 151-164
28. Spencer CA, Lopresti JS, Patel A, Guttler RB, Eigen A, Shen D, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990 ; 70 (2). 453-460
29. Kimura T, Kanda T, Kotajima N, Kuwabara A, Fukumura Y, Kobayashi I. Involvement of circulating interleukina6 and its receptor in the development of euthyroid sick syndrome in patients with acute myocardial infarction. Eur J Endocrinol. 2000 ; 143 (2). 179-184
30. Karga H, Papaioannou P, Venetsanou K, Papandroulaki F, Karaloizos L, Papaioannou G, et al. The role of cytokines and cortisol in the non-thyroidal illness syndrome following acute myocardial infarction. Eur J Endocrinol. 2000 ; 142 (3). 236-242
31. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet. 2001 ; 358 (9285). 861-865
32. Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJ, Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci U S A. 1981 ; 78 (4). 2591-2595
33. Volzke H, Robinson DM, Spielhagen T, Nauck M, Obst A, Ewert R, et al. Are serum thyrotropin levels within the reference range associated with endothelial function?. Eur Heart J. 2009 ; 30 (2). 217-224
34. Jarvisalo MJ, Harmoinen A, Hakanen M, Paakkunainen U, Viikari J, Hartiala J, et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol. 2002 ; 22 (8). 1323-1328
35. Dardano A, Ghiadoni L, Plantinga Y, Caraccio N, Bemi A, Duranti E, et al. Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006 ; 91 (10). 4175-4178
36. Napoli R, Apuzzi V, Bosso G, D'Anna C, De SA, Pirozzi C, et al. Recombinant human thyrotropin enhances endothelial-mediated vasodilation of conduit arteries. J Clin Endocrinol Metab. 2009 ; 94 (3). 1012-1016
37. Westerink J, van der Graaf Y, Faber DR, Visseren FL, SMART study group. The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease. Eur J Clin Invest. 2011 ; 41 (2). 159-166
38. Nannipieri M, Cecchetti F, Anselmino M, Camastra S, Niccolini P, Lamacchia M, et al. Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and/or type 2 diabetes: effects of weight loss. Int J Obes (Lond). 2009 ; 33 (9). 1001-1006
39. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet. 2005 ; 366 (9497). 1640-1649
40. Faber DR, van der Graaf Y, Westerink J, Visseren FL. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. Atherosclerosis. 2010 ; 212 (1). 274-280
41. Grundy SM, Barnett JP. Metabolic and health complications of obesity. Dis Mon. 1990 ; 36 (12). 641-731
42. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996 ; 97 (11). 2601-2610